Posts by Steven Chervenick
Pleural Mesothelioma and Brain Metastasis
When people are diagnosed with mesothelioma, it is common for the disease to spread. This occurs in around 60 percent of people, but it does not usually spread to the brain. Researchers in Great Britain believe doctors should be focusing on cerebral metastasis in mesothelioma patients in addition to other areas of the body because…
Read MoreEnzyme and Chemotherapy Combination for Mesothelioma
Pleural mesothelioma sufferers could improve their survival by as much as 30 percent when treated with the latest cancer enzyme and chemotherapy. In a recent study known as ATOMIC Meso, ADI-PEG 20 showed effectiveness when used for sarcomatoid and biphasic mesothelioma, the two most resistive to treatment. The enzyme is able to limit an amino…
Read MoreA Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Primary Outcome Measures Number of participants with adverse events (AEs) [ Time Frame: Through 30 days after the last study treatment; approximately 7 months ] Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Number of participants with laboratory abnormalities [ Time Frame: Through 30 days…
Read MoreSTAR-101 Could Make CAR T-Cell Therapy More Effective for Mesothelioma Patients
Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the University of Pennsylvania. The Food and Drug Administration gave orphan drug status to SynKIR-110, a CAR T-cell therapy utilized for solid tumors (including mesothelioma) that…
Read MoreSynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Primary Outcome Measures Safety and feasibility of SynKIR-110 [ Time Frame: Date of enrollment through date of last patient visit, up to 36 months. ] • The incidence, frequency, and severity of TEAEs, incidence of AEs related to native mesothelin-expressing tissues, • Incidence of CRS and/or neurologic toxicity Secondary Outcome Measures Define the MTD or MFD of SynKIR-110 [ Time Frame: Date…
Read MoreCARD is Performing Asbestos Screenings Throughout Montana
Asbestos exposure screenings are being performed in Libby, Montana. The Center for Asbestos Related Disease (CARD) is going around the state offering screenings to people who cannot or are not willing to travel. Libby, Montana was heavily contaminated with asbestos because of a contaminated vermiculite mine operating in the area. It is one of the…
Read MoreA Phase 1 Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Primary Outcome Measures Dose limiting toxicity (DLT) of PRT3645 [ Time Frame: Baseline through Day 28 ] Dose limiting toxicity will be evaluated over the 28-day observation period Safety and tolerability of PRT3645: AEs, CTCAE Assessments [ Time Frame: Baseline through approximately 2 years ] Safety and tolerability will be evaluated by incidence of DLTs, laboratory measurements, severity of adverse events (AEs) according…
Read MoreA Protein Could Make Chemotherapy More Effective on Mesothelioma
Mesothelioma is a rare cancer with a poor life expectancy. People diagnosed with pleural mesothelioma usually live for four to 18 months after diagnosis. The poor survival is a result of the aggressive nature of the cancer and that it is usually diagnosed at a late stage when it is less treatable. Once mesothelioma progresses,…
Read MoreMesothelioma Specialty Centers Offer Better Care for Mesothelioma Patients
When mesothelioma patients are treated at mesothelioma specialty centers, they experience better care and survive longer. Kaiser Permanente Northern California Health System compared its performance before and after it transitioned into a specialty care center for mesothelioma. The doctors found a dramatic improvement in patients after the transition. Results were published in the Journal for…
Read MoreTTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study (TIGER Meso)
Primary Outcome Measures Time from diagnosis of pleural mesothelioma to death of any cause as median overall survival time. [ Time Frame: 54 Months ] Secondary Outcome Measures Number of TTFields treatment-related SAEs, as assessed by the CEC, within total observation period, standardized to average annual incidences. [ Time Frame: 3 years + 18 months follow up ] Changes in quality of life…
Read More